Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal.
Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal.
Vet Pathol. 2022 Nov;59(6):903-914. doi: 10.1177/03009858221117858. Epub 2022 Aug 16.
This study evaluated the expression of vimentin and Ki-67 proliferative index (PI) by immunohistochemistry in 30 canine gastric carcinomas (GCs) and a possible association with clinical and pathological features and patient's survival time. Vimentin immunoreactivity was assessed in neoplastic cells (in primary lesions, emboli, and metastases) and tumor-associated stroma (TAS) of canine GCs. Ki-67 PI was quantified in the neoplastic epithelial component. Vimentin immunolabeling in neoplastic cells was found in 30% of the primary lesions, in 82% of the neoplastic emboli, and in 50% of the metastases; in TAS, it was observed in all cases. A mean of 16% of the TAS was immunolabeled for vimentin. High vimentin immunolabeling in the TAS (>16%) was detected in 40% of cases. The average value of Ki-67 PI was 50%, and 80% of the lesions had Ki-67 PI above 20%. Vimentin immunolabeling in neoplastic cells was more frequent in less-differentiated carcinomas (diffuse [29%] and indeterminate types [75%]) than well-differentiated carcinomas (intestinal type [0%], .049). No significant differences were observed in vimentin immunolabeling in the TAS or Ki-67 PI according to histological diagnosis, depth of invasion, presence of neoplastic emboli or metastases. However, vimentin immunolabeling in the TAS was positively correlated with Ki-67 PI ( = .394, = .031). Furthermore, a moderate negative correlation was observed between Ki-67 PI and survival time ( = -0.540). Our results suggest that vimentin and Ki-67 PI have potential for providing prognostic information in cases of canine GCs.
本研究通过免疫组织化学评估了 30 例犬胃腺癌（GC）中波形蛋白和 Ki-67 增殖指数（PI）的表达，并探讨了其与临床病理特征和患者生存时间的可能关联。在犬 GC 的原发性病变、肿瘤栓子和转移灶中的肿瘤细胞（neoplastic cells）和肿瘤相关基质（tumor-associated stroma，TAS）中评估了波形蛋白免疫反应性。Ki-67 PI 在肿瘤上皮成分中进行了量化。在原发性病变中，有 30%的病例存在肿瘤细胞的波形蛋白免疫标记，82%的肿瘤栓子存在，50%的转移灶存在；在 TAS 中，所有病例均存在。TAS 的平均 16%被标记为波形蛋白免疫阳性。在 40%的病例中，TAS 的高波形蛋白免疫标记（>16%）被检测到。Ki-67 PI 的平均值为 50%，80%的病变 Ki-67 PI 高于 20%。在分化程度较低的癌（弥漫型[29%]和不定型[75%]）中，肿瘤细胞的波形蛋白免疫标记比分化程度较高的癌（肠型[0%]，.049）更常见。在 TAS 中的波形蛋白免疫标记或 Ki-67 PI 方面，根据组织学诊断、浸润深度、肿瘤栓子或转移的存在，未观察到显著差异。然而，TAS 中的波形蛋白免疫标记与 Ki-67 PI 呈正相关（ =.394， =.031）。此外，Ki-67 PI 与生存时间呈中度负相关（ = -0.540）。我们的结果表明，波形蛋白和 Ki-67 PI 在犬胃腺癌病例中具有提供预后信息的潜力。
